Welcome to the Kick-off Meeting of the Horizon 2020 Research and Innovation Action
‘TTV GUIDE TX’
We are a team of transplant physicians, virologists and health care industry professionals. Together we aim to establish a new tool to quantify the activity of the immune system in kidney transplant recipients.
We believe that the recently discovered Torque Teno Virus (TTV) can do this job. TTV is unique: it is naturally occurring in the blood of every healthy person and every kidney transplant recipient, but it causes no disease. If the patient’s immune system is strong, the
TTV load is low; this indicates a risk for organ rejection.
If the immune system is weak, the TTV load is high; this indicates a risk for infection. We believe that the quantification of the TTV in the blood of kidney transplant recipients can help optimize immunosuppressive drugs and thus reduce infections and rejection.
Within our EU funded project TTV guided dosing of immunosuppressive drugs will be tested in a clinical trial including hundreds of kidney transplant recipients from all over Europe. Once established in routine clinical care, TTV guidance might reduce thousands of infections and kidney transplant rejections each year. In the future TTV might not only help kidney transplant
recipients, but also patients with liver, heart and lung transplantation, and guide therapy in autoimmune, infectious and oncologic diseases.
Gregor Bond and Georg Melzer-Venturi for the TTV GUIDE TX consortium
Further Information, Registration and Programm.